

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Fischer-Zoth Diagenosysteme GmbH		09/28/2004	CORPORATION: FEDERAL REPUBLIC GERMANY
RECEIVING PARTY DATA			
Name:	Natus Medical Incorporated		
Street Address:	1501 Industrial Road		
City:	San Carlos		
State/Country:	CALIFORNIA		
Postal Code:	94070		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	76280207	AOAE	
Serial Number:	76366188	COCHLEA-SCAN	
Serial Number:	76280208	ECHO-SCREEN	
Serial Number:	76280206	FISCHER-ZOTH	
CORRESPONDENCE DATA			
Fax Number:	(530)750-3793		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	530-750-3661		
Email:	mathew@temmermanlaw.com		
Correspondent Name:	Mathew J. Temmerman		
Address Line 1:	423 E Street		
Address Line 4:	Davis, CALIFORNIA 95616		
NAME OF SUBMITTER:	Mathew J. Temmerman		
Signature:	/Mathew J. Temmerman/		

OP \$115.00 76280207

Date:

05/26/2008

Total Attachments: 3

source=Form_8K_10344#page1.tif

source=Form_8K_10344#page2.tif

source=Form_8K_10344#page3.tif



8-K

NATUS MEDICAL INC filed this Form 8-K on 09/30/04

<< Previous Page | Next Page >>

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) September 28, 2004

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-33001
(Commission File Number)

77-0154833
(IRS Employer
Identification No.)

1501 Industrial Road, San Carlos, California 94070
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (650) 802-0400

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.01. COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

On September 28, 2004, pursuant to a stock purchase agreement, Natus Medical Incorporated acquired Fischer-Zoth GmbH and affiliated entities for cash of \$5.5 million. Fischer-Zoth is a manufacturer of otoacoustic emissions products, with operations headquartered near Munich, Germany. Peter Zoth, President and co-founder of Fischer-Zoth will remain with the company as managing director. The stock was acquired from Mr. Zoth and several other shareholders of the closely-held entities.

ITEM 8.01. OTHER EVENTS.

On September 29, 2004, Natus Medical Incorporated (the “Company”) issued a press release announcing the acquisition of Fischer-Zoth GmbH. A copy of the press release is furnished as an exhibit to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated September 29, 2004 announcing the acquisition of Fischer-Zoth GmbH.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NATUS MEDICAL INCORPORATED

Dated: September 29, 2004

By: /s/ Steven J. Murphy

Steven J. Murphy
Vice President, Finance and Principal
Accounting Officer

-3-

Exhibit 99.1

NATUS MEDICAL ACQUIRES FISCHER-ZOTH Company Adds Leading OAE Technology to its Portfolio

SAN CARLOS, Calif. (September 29, 2004) – Natus Medical Incorporated (Nasdaq NM: BABY) today announced the acquisition for cash of privately held Fischer-Zoth GmbH, a leading manufacturer of otoacoustic emissions (OAE) products. The acquisition adds to Natus’ growth opportunities by broadening its product offerings and supporting expansion into new markets. Natus believes the acquisition will be accretive to earnings in 2005.

Under terms of the acquisition, Natus will retain Fischer-Zoth’s operations, which are headquartered near Munich, Germany, as well as its existing sales channels. Fischer-Zoth co-founder Peter Zoth will continue on as managing director of the organization. Fischer-Zoth currently has 20 employees and recorded revenue of approximately \$3.1 million during calendar 2003.

“We believe Fischer-Zoth’s complementary products will round out our hearing screening product portfolio and give Natus a stronger European presence,” stated Jim Hawkins, president and chief executive officer of Natus. “Fischer-Zoth has built a growing, profitable operation with strong margins and a reputation for producing high-quality products. Natus has become the world leader in newborn hearing screening through our proprietary AABR® technology. Now we can build on this position by bringing the Fischer-Zoth products into the pediatric and diagnostics markets.”

Founded in 1995, Fischer-Zoth develops and manufactures products for the detection and diagnosis of hearing disorders that it sells through distributors in more than 40 countries. As a developer of proprietary, patented signal processing software, the company improved traditional OAE technology, which has enhanced the performance of its products over other OAE devices. Since its inception, Fischer-Zoth has sold more than 3,500 OAE devices worldwide. Fischer-Zoth devices also utilize a disposable supply, generating a recurring revenue stream.

“We are excited to be joining Natus, a company that shares our passion for quality, innovation and market leadership,” commented Mr. Zoth. “Through this business combination, we will be able to leverage Natus’ direct sales organization and our existing distribution partners to more quickly penetrate the global market for our hearing screening and diagnostic products.”

Natus expects to record one-time charges during the 2004 third quarter related to the acquisition, primarily for the write-off of acquired in-process research and development, in the range of \$600,000 to \$1.0 million. These charges were not included in financial guidance previously provided by the Company.

About Natus Medical

Natus develops, manufactures, and markets products for the detection, treatment, monitoring, and tracking of common disorders in newborns. Natus markets and sells its products worldwide through a direct sales force in the U.S. and the U.K. and through distributors in over 30 other countries. Additional information about Natus Medical can be found at www.natus.com.

Natus' product lines include: ALGO[®] Newborn Hearing Screeners; MiniMuffs[®] Neonatal Noise Attenuators; neoBLUE[™] LED Phototherapy devices; Biliband[™] Eye Protectors; Oxydome[™], Oxypod[™], Oxy-Igloo[™], and Foldadome[™] neonatal oxygen hoods; Igloo[™] neonatal heatshield; Neometrics[™] data management products: Metabolic Screening Database System (MSDS)[™], Case Management System (CMS)[™], Web Based Electronic Birth Page (WebEBP)[™], and Voice Response System (VRS)[™]; Fischer-Zoth products: Echo-Screen[®], Audio System DPOAE, and Cochlea-Scan[®].

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 including, but not limited to, charges associated with the Fischer-Zoth acquisition, and the impact of the acquisition on future earnings, new product offerings, and expansion into new markets. These statements relate to future events or Natus' future financial performance or results, and involve known and unknown risks, uncertainties, and other factors that may cause Natus' actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. The actual operating results could differ materially due to a number of factors, including the difficulty in integrating acquired businesses, including Fischer-Zoth, into our business, the risks associated with expanding operations into other countries and doing business in foreign countries, continued growth of demand, or absence of continued growth of demand, for newborn hearing screening equipment, acceptance of Natus' existing products, the successful development, introduction and widespread market acceptance of Natus' new products, dependence on our ALGO, Neometrics and Fischer-Zoth products for substantially all of our revenue, the successful addition of products to Natus' established distribution channel, domestic and global economic conditions, competition from other companies, the failure of states or foreign countries to adopt mandates or guidelines requiring screening for the disorders for which Natus' products screen, the failure of third party payors to provide adequate reimbursement for the use of Natus' products, adverse changes in Natus' relationships with its suppliers, reduced revenue as a result of discounts given to organizations representing several end customers for Natus' products, failure to obtain necessary regulatory clearances or approvals, adverse changes in Natus' relationships with its distributors, difficulty integrating acquired businesses into our business, performance of newly acquired products and technologies, difficulty and increased expenses relating to foreign operations, and product liability and intellectual property disputes or litigation. Natus disclaims any obligation to update information contained in any forward-looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2003, and its quarterly reports on Form 10-Q, and from time to time in other reports filed by Natus with the U.S. Securities and Exchange Commission.

Natus[®], AABR[®], ALGO[®], ALGO 1e[®], ALGO 2[®], ALGO DataBook[®], 70/40[®], Ear Couplers[®], Flexicoupler[®], Jelly Tab[®], Jelly Button[®], and MiniMuffs[®] are registered trademarks of Natus. Natus Elite[™], Convert2Natus[™], neoBLUE[™], neoBLUE mini[™], Neometrics[™], Metabolic Screening Database System (MSDS)[™], Case Management System (CMS)[™], Voice Response System (VRS)[™], Web Electronic Birth Page (Web-EBP)[™], and Accuwell[™] are non-registered trademarks of Natus. Solutions for Newborn CareSM is a non-registered service mark of Natus. Echo-Screen[®], AOAE[®], and Cochlea-Scan[®] are registered trademarks of Fischer-Zoth GmbH.

###

<< Previous Page | Next Page >>